{"id":11452,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:43:54","modified_gmt":"2025-10-04T08:43:54","slug":"hipertermije-kakovost-zivljenja-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/sl\/hipertermije-kakovost-zivljenja-qol\/","title":{"rendered":"Vpliv hipertermije na kakovost \u017eivljenja (QoL): Laj\u0161anje bole\u010dine, zmanj\u0161anje utrujenosti in adjuvantne imunolo\u0161ke koristi"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Vpliv hipertermije na kakovost \u017eivljenja (QoL): Laj\u0161anje bole\u010dine, zmanj\u0161anje utrujenosti in adjuvantne imunolo\u0161ke koristi\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermija, Onkologija, klini\u010dno presku\u0161anje Faze III, QoL, bole\u010dina, E-E-A-T\"\n      \/*... Shema FAQPage bi bila dodana posebej za razdelek Pogosta Vpra\u0161anja *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Avtoriteta in Strokovnost (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Avtor: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , dr. med., in <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vpliv hipertermije na kakovost \u017eivljenja (QoL): Laj\u0161anje bole\u010dine, zmanj\u0161anje utrujenosti in adjuvantne imunolo\u0161ke koristi<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V sodobni onkologiji se zdravljenje raka osredoto\u010da na optimalno ravnovesje med<a href=\"https:\/\/andromedichyperthermia.com\/sl\/hipertermija-prezivetje-bolnikih\/\"> Pre\u017eivetjem (OS\/DFS)<\/a> in <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kakovostjo \u017divljenja (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija (HT) predstavlja edinstveno adjuvantno modaliteto, ki je z velikimi klini\u010dnimi presku\u0161anji ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/hipertermije-preskusanj-faze-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faza III RCT-ji<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) dokazala izbolj\u0161anje QoL na ve\u010d ravneh: nadzor simptomov, splo\u0161no funkcionalno stanje in odli\u010den varnostni profil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Glavna Paliativna Korist: Nadzor Bole\u010dine (dokazi ravni A1 iz klini\u010dnih presku\u0161anj Faze III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatska bole\u010dina v kosteh poslab\u0161a QoL. Lokoregionalna RF hipertermija, v kombinaciji z Radioterapijo (RT), zagotavlja vrhunski paliativni nadzor, v skladu z <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0161tudijo Faze III, ki so jo objavili Chi MS in sod<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Kazalnik\/Izbolj\u0161anje Bole\u010dine<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (HT)<\/span><\/span><\/th>\n<th>QoL Vpliv<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Stopnja Popolnega Odziva (CR) po 3 Mesecih<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (ni\u010delna ocena bole\u010dine)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533 % pove\u010danje mo\u017enosti popolne odprave bole\u010dine.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje Laj\u0161anja Bole\u010dine<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: 55 dni\/7,9 tedna<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: Ni dose\u017eena v 24. tednu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje laj\u0161anja se potroji, kar zmanj\u0161a odvisnost od analgetikov.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Leta <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 so Sahinbas in sodelavci objavili \u0161tudijo Faze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> za bole\u010dine pri kostnih metastazah, predvsem pri raku dojke in prostate, z uporabo WBHT wIRA hipertermije poleg RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na podlagi te \u0161tudije je skupina, ki je prejemala samo radioterapijo (RT), izkazovala najintenzivnej\u0161o bole\u010dino. \u0160tudija je bila zaklju\u010dena po vklju\u010ditvi 61 bolnikov, 5 let po prvem vklju\u010denju (april 2016 \u2013 februar 2021). Kon\u010dno je stopnja CR v skupini RT + WBH pokazala najpomembnej\u0161o razliko v primerjavi s samo RT, in sicer 47,4 % v primerjavi s 5,3 %, v 2 mesecih po zdravljenju (vrednost P &lt; 0,05). \u010cas do popolnega laj\u0161anja bole\u010dine je bil 10 dni za RT + WBH, medtem ko kon\u010dna to\u010dka ni bila dose\u017eena v skupini RT monoterapije. Progresija bole\u010dine ali stabilnost bolezni sta bili opa\u017eeni pri polovici bolnikov v skupini RT v 4 tednih po zdravljenju. Vendar pa je bil ta rezultat pri bolnikih RT + WBHT blizu ni\u010dle v dveh mesecih po zdravljenju.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zaklju\u010dki:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT sta pokazala pomembno pove\u010danje laj\u0161anja bole\u010dine in kraj\u0161i \u010das odziva v primerjavi s samo RT pri bolnikih z metastatskimi kostnimi lezijami.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Kazalnik\/Izbolj\u0161anje Bole\u010dine<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Vpliv<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Stopnja Popolnega Odziva (CR) po 2 Mesecih<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (ni\u010delna ocena bole\u010dine)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % pove\u010danje<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * mo\u017enosti popolne odprave bole\u010dine.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u010cas do popolnega laj\u0161anja bole\u010dine<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ni bilo dose\u017eeno<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dni<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Pomembna in Hitra Prednost<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje Laj\u0161anja Bole\u010dine\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: 28 dni\/4 tedne pri polovici bolnikov<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: Ni dose\u017eena v 24. tednu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje laj\u0161anja * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">se pove\u010da \u0161estkrat<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, kar zmanj\u0161a odvisnost od analgetikov.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Izbolj\u0161anje Funkcionalnega Stanja in Zmanj\u0161anje Utrujenosti<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Korist HT na QdL je neposredno merljiva s standardiziranimi vpra\u0161alniki (EORTC QLQ-C30), ki ka\u017eejo izbolj\u0161anje splo\u0161nega stanja (Fizi\u010dna Funkcija, Utrujenost in Anksioznost):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Bistveno Izbolj\u0161ana QoL (modulirana RF hipertermija mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomizirano klini\u010dno presku\u0161anje Modulirane RF Hipertermije (mEHT) pri Raku Materni\u010dnega Vratu (LACC) je poro\u010dalo o pomembnem izbolj\u0161anju dolgoro\u010dnih QoL rezultatov, pri \u010demer so bolniki poro\u010dali o bolj\u0161ih rezultatih na lestvicah Fizi\u010dne in Emocionalne Funkcije.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nadzor Utrujenosti in Imunomodulacija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija Celega Telesa (WBHT) in HT na splo\u0161no pozitivno vplivata na kroni\u010dno utrujenost (CRF) z modulacijo proinflamatornih citokinov (IL-6, TNF-alfa). HT prav tako pomaga ohranjati in izbolj\u0161evati rezultate na lestvicah Fizi\u010dne in Emocionalne Funkcije dolgoro\u010dno.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hitra Emocionalna Ozdravitev (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Po ve\u010djih kirur\u0161kih posegih, ki vklju\u010dujejo HT (HIPEC), se emocionalna QoL ponavadi hitro izbolj\u0161a, za\u010den\u0161i \u017ee *3 mesece po operaciji, pogosto presega izhodi\u0161\u010dno raven.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolidacija Dolgoro\u010dnih QoL Koristi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Podatki iz resni\u010dnega sveta in klini\u010dna presku\u0161anja pri napredovalih rakih potrjujejo vlogo hipertermije pri stabilizaciji in izbolj\u0161anju dolgoro\u010dne QoL:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativni Vpliv po 12 Mesecih:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Obse\u017ena analiza bolnikov, zdravljenih z namenom ozdravitve (RCT + HT), je pokazala pomembno izbolj\u0161anje, ohranjeno skozi *12-mese\u010dno obdobje, pri rezultatih na podlestvicah QoL, ki ocenjujejo **Emocionalno Funkcijo, Socialno Funkcijo* in *Nesanico (SL)*, v primerjavi z onkolo\u0161ko referen\u010dno populacijo EORTC.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Paliativne Koristi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V paliativnem kontekstu je dodajanje HT standardnemu zdravljenju privedlo do klini\u010dno relevantnega izbolj\u0161anja *Bole\u010dine (PA)* in zmanj\u0161anja *Finan\u010dnih Te\u017eav (FI)* *3 mesece po zdravljenju*, kar je prispevalo k bolj\u0161emu splo\u0161nemu stanju bolnika.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Izbolj\u0161ana QoL pri Napredovalih Boleznih (Kolorektalni Karcinom):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V \u0161tudiji, ki je ocenjevala Visokofrekven\u010dno Hipertermijo, podprto s kemoterapijo pri bolnikih z rakom debelega \u010drevesa in danke v srednjem in napredovalem stadiju, je skupina, ki je prejela kombinacijo, pokazala bistveno vi\u0161je (izbolj\u0161ane) QoL rezultate po 4 ciklusih zdravljenja, kar dokazuje, da HT u\u010dinkovito izbolj\u0161a QoL, poleg terapevtskih u\u010dinkov, hkrati pa ohranja bolj\u0161o varnost.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvantne Biolo\u0161ke Koristi in Vi\u0161ji Terapevtski Indeks<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksimizira letalnost zdravljenja brez znatnega pove\u010danja tveganja za hudo toksi\u010dnost (Stopnja 3-4), s \u010dimer ohranja visok Terapevtski Indeks:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Potrjena Varnost (klini\u010dna presku\u0161anja Faze III):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-analize pri raku materni\u010dnega vratu dokazujejo brez pomembne razlike v akutni ali pozni toksi\u010dnosti (RR Toksi\u010dnost 1.01)[6]. Varnostni profil se ohranja pri Raku Rektuma[7] in v presku\u0161anjih Raka Trebu\u0161ne Slinavke.[8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ohranjanje Organov:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Pri Raku Rektuma dodatek HT k neoadjuvantni kemoradioterapiji pove\u010da 5-letno Pre\u017eivetje Brez Kolostome (CFS) s 69,0 % na 87,7 %, kar je pomembna funkcionalna korist za QoL.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abscopalni U\u010dinek (Podoben Cepivu):<\/strong> HT spro\u017ei imunogeno celi\u010dno smrt, spro\u0161\u010da Beljakovine Toplotnega \u0160oka (HSPs), ki aktivirajo citotoksi\u010dne celice T CD8+. Ta sistemski imunolo\u0161ki primarni u\u010dinek prispeva k nadzoru preostale bolezni in je bistvena adjuvantna korist.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zaklju\u010dek: Na Pacienta Osredoto\u010dena Terapija<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integracija Hipertermije v onkolo\u0161ki protokol predstavlja napredno, na dokazih temelje\u010do strategijo, ki ne samo, da izbolj\u0161a Pre\u017eivetje, temve\u010d tudi zagotavlja robusten nadzor simptomov in ohranja Kakovost \u017divljenja. Laj\u0161anje bole\u010dine, nadzor utrujenosti in odli\u010den varnostni profil naredijo HT bistven element celostne oskrbe onkolo\u0161kega bolnika.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vabimo vas, da se posvetujete z na\u0161imi strokovnjaki za integracijo Hipertermije v va\u0161 protokol, z namenom maksimiziranja tako u\u010dinkovitosti kot Kakovosti \u017divljenja.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT Garancija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ta vsebina temelji na objavljenih podatkih iz randomiziranih in prospektivnih klini\u010dnih presku\u0161anj Faze III, ki uporabljajo standardizirane instrumente za merjenje Kakovosti \u017divljenja (EORTC QLQ-C30). Popolni viri so integrirani z neposrednimi povezavami na izvirne publikacije.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Viri:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Avtoriteta in Strokovnost (EEAT): Avtor: Dr. Veronica Iatan , dr. med., in Cristian Gologan M.Sc , Andromedichyperthermia Vpliv hipertermije na kakovost \u017eivljenja (QoL): Laj\u0161anje bole\u010dine, zmanj\u0161anje utrujenosti in adjuvantne imunolo\u0161ke koristi V sodobni onkologiji se zdravljenje raka osredoto\u010da na optimalno ravnovesje med Pre\u017eivetjem (OS\/DFS) in Kakovostjo \u017divljenja (QoL). Hipertermija (HT) predstavlja edinstveno adjuvantno modaliteto, ki&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,1007,31],"tags":[1063,1008,1009,1010,772,1062,773,1013,1014],"class_list":["post-11452","post","type-post","status-publish","format-standard","hentry","category-news-sl","category-studii-clinice-sl","category-uncategorized-sl","tag-bolecina","tag-calitatea-vietii-sl","tag-durere-sl","tag-hipertermie-oncologica-sl","tag-hipertermija-sl","tag-klinicno-preskusanje-faze-iii","tag-onkologija-sl","tag-qol-sl","tag-studii-faza-iii-sl"],"gutentor_comment":27,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts\/11452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/comments?post=11452"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts\/11452\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/media?parent=11452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/categories?post=11452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/tags?post=11452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}